Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R)

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 642-647

  Bolignano, Davide ^a   Medici, Maria Antonietta ^a   Coppolino, Giuseppe ^a   Sciortino, Maria Teresa ^a   Merlo, Francesca Marino ^a   Campo, Susanna ^a   Donato, Valentina ^a   Venuti, Assunta ^a   Sturiale, Alessio ^a   Zaccaria, Daniela ^a   Buemi, Antoine ^a   Lacquaniti, Antonio ^a   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cell proliferation; Renal cancer; V2 R antagonist; V2 receptor; Vasopressin

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; DESMOPRESSIN; SATAVAPTAN; VASOPRESSIN V2 RECEPTOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTIDIURETIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEAMINO ARGININE VASOPRESSIN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KIDNEY NEOPLASMS; MALE; RECEPTORS, VASOPRESSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASOPRESSINS;

EID: 78149408240     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.12.014     Document Type: Article

References (23)

1. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000, 11:406-410.
2. North W.G. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol 2000, 85:27S-40S.
3. Treschan T.A., Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology 2006, 105:599-612.
4. North W.G., Fay M.J., Du J. MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 1999, 20:837-842.
5. Keegan B.P., Akerman B.L., Pequeux C., et al. Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies. Breast Cancer Res Treat 2006, 95:265-277.
6. Pequeux C., Keegan B.P., Hagelstein M.T., et al. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 2004, 11:871-885.
7. Perraudin V., Delarue C., De Keyzer Y., et al. Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: In vivo and in vitro studies. J Clin Endocrinol Metab 1995, 80:2661-2667.
8. McLaughlin J.K., Lipworth L., Tarone R.E. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006, 33:527-533.
9. Westenfelder C., Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000, 58:647-657.
10. Michael A., Politi E., Havranek E., et al. Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int 2007, 100:291-294.
11. Langner C., Ratschek M., Rehak P., et al. Steroid hormone receptor expression in renal cell carcinoma: An immunohistochemical analysis of 182 tumors. J Urol 2004, 171(2 Pt 1):611-614.
12. Keller G., Schally A.V., Gaiser T., et al. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res 2005, 11:5549-5557.
13. Rosendahl A., Forsberg G. Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int J Oncol 2004, 25:1327-1336.
14. Schally A.V. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008, 40:315-322.
15. Belibi F.A., Reif G., Wallace D.P., et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004, 66:964-973.
16. Yamaguchi T., Pelling J.C., Ramaswamy N.T., et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000, 57:1460-1471.
17. Gattone V.H., Wang X., Harris P.C., et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003, 9:1323-1326.
18. Torres V.E., Wang X., Qian Q., et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004, 10:363-364.
19. Truong L.D., Choi Y.J., Shen S.S., et al. Renal cystic neoplasms and renal neoplasms associated with cystic renal diseases: Pathogenetic and molecular links. Adv Anat Pathol 2003, 10:135-159.
20. Soderdahl D.W., Thrasher J.B., Hansberry K.L. Bilateral renal cell carcinoma in autosomal dominant polycystic kidney disease. A case report and literature review. Am J Nephrol 1997, 17:96-99.
21. Umemura S., Segawa Y., Ueoka H., et al. Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer. J Cancer Res Clin Oncol 2007, 133:519-524.
22. Soupart A., Gross P., Legros J.J., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006, 1:1154-1160.
23. Bolignano D., Coppolino G., Criseo M., et al. Aquaretic agents: What's beyond the treatment of hyponatremia?. Curr Pharm Des 2007, 13:865-871.